Darryl Maher

2.1k citations

23 papers · 1.3k indexed · 1 hit paper · h-index 13

Impact in

Immunology top 5%
- Immune Response and Inflammation
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
Hematology top 5%

Papers in ⓘ

Immunology 10
- T-cell and B-cell Immunology 3
- Immune Cell Function and Interaction 3
- Immunotherapy and Immune Responses 3
- Immune Response and Inflammation 3
Epidemiology 8

Co-authors: Jonathan Cebon (8 shared papers)Ashley R. Dunn (1 shared paper)Edouard G. Stanley (1 shared paper)John A.M. Gall (1 shared paper)Vincent Sinickas (1 shared paper)D Metcalf (1 shared paper)Graham J. Lieschke (1 shared paper)D Grail (1 shared paper)
Journals: Human Vaccines & Immunotherapeutics (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Journal of Clinical Oncology (2 papers)Critical Care Medicine (2 papers)British Journal of Haematology (1 paper)
Partner nations: Australia Belgium United Kingdom

In The Last Decade

Darryl Maher

22 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. 1994 · 678 citations

Peers

Countries citing papers authored by Darryl Maher

Since Specialization

Citations

This map shows the geographic impact of Darryl Maher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darryl Maher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darryl Maher more than expected).

Fields of papers citing papers by Darryl Maher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darryl Maher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darryl Maher. The network helps show where Darryl Maher may publish in the future.

Co-authors

The 25 scholars most cited alongside Darryl Maher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Darryl Maher Line = papers co-authored together Darryl Maher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proceedings of the National Academy of Sciences ·Edouard G. Stanley, Graham J. Lieschke, D Grail, D Metcalf, G. S. Hodgson, John A.M. Gall, Darryl Maher, Jonathan Cebon, Vincent Sinickas, Ashley R. Dunn Hit paper breakdown →	1994	678
2	Production of IL‐10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma International Journal of Cancer ·Qiyuan Chen, Vincent C. Daniel, Darryl Maher, Peter Hersey	1994	205
3	Endogenous haemopoietic growth factors in neutropenia and infection British Journal of Haematology ·Jonathan Cebon, Judith E. Layton, Darryl Maher, George Morstyn	1994	129
4	Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: Relation to disease severity, multiple organ dysfunction, and mortality Critical Care Medicine ·Jeffrey Presneill, Paul Waring, Judith E. Layton, Darryl Maher, Jonathan Cebon, Nerina Harley, John Wilson, J. F. Cade	2000	38
5	Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. PubMed ·R. Basser, L. Bik To, C. Glenn Begley, Christopher A. Juttner, Darryl Maher, Jeff Szer, Jonathan Cebon, John P. Collins, I. Steele Russell, Ian Olver	1995	31
6	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. PubMed ·Emmanuel J. Favaloro, J. V. Lloyd, John Rowell, Ross Baker, K.A. Rickard, Geoff Kershaw, Alison Street, Kate Scarff, Giulio Barrese, Darryl Maher, Andrew J. McLachlan	2007	29
7	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder Thrombosis and Haemostasis ·J. V. Lloyd, John Rowell, Ross Baker, K.A. Rickard, Geoff Kershaw, Alison Street, Kate Scarff, Giulio Barrese, Darryl Maher, Andrew J. McLachlan, Emmanuel J. Favaloro	2007	29
8	Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection EBioMedicine ·Steven Rockman, Sue Lowther, Sarina Camuglia, Kirsten Vandenberg, Shirley M. Taylor, Louis Fabri, Sylvia Miescher, Martin J. Pearse, Deborah Middleton, Stephen J. Kent, Darryl Maher	2017	25
9	Human interleukin-4: An immunomodulator with potential therapeutic applications PubMed ·Darryl Maher, Ian D. Davis, Andy Boyd, George Morstyn	1991	24
10	Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia Clinical & Experimental Immunology ·Paul Waring, Jeffrey Presneill, Darryl Maher, Judith E. Layton, Jonathan Cebon, Lyn Waring, D Metcalf	1995	24
11	Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up Journal of Clinical Oncology ·Russell L. Basser, L. Bik To, John P. Collins, C. Glenn Begley, D. Keefe, Jonathan Cebon, John Bashford, Simon Durrant, Jeff Szer, Dusan Kotasek, Christopher A. Juttner, Ian Russell, Darryl Maher, Ian Olver, William Sheridan, Richard M. Fox, Michael D. Green	1999	21
12	KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma Journal of Clinical Oncology ·Kerrie Clarke, Russell L. Basser, Craig Underhill, Peter Mitchell, Jane Bartlett, Lawrence Cher, Michael Findlay, D. Dalley, Malcolm Pell, Michael Byrne, Howard Geldard, John S. Hill, Darryl Maher, Richard M. Fox, Michael D. Green, Andrew H. Kaye	1999	14
13	The Response of Human B Cells to Interleukin 4 is Determined by their Stage of Activation and Differentiation Scandinavian Journal of Immunology ·Darryl Maher, Beverley L. Pike, Andy Boyd	1990	13
14	The use of hyperimmune serum for severe influenza infections* Critical Care Medicine ·Steven Rockman, Darryl Maher, Deborah Middleton	2011	11
15	Do Australian immunoglobulin products meet international measles antibody titer standards? Human Vaccines & Immunotherapeutics ·Megan K Young, Joseph Bertolini, Pushpa Kotharu, Darryl Maher, Allan W. Cripps	2016	10
16	Impact of manufacturing improvements on clinical safety of albumin: Australian pharmacovigilance data for 1988–2005 Critical Care and Resuscitation ·Yan Che, Fiona J. Wilson, Joseph Bertolini, Peter B. Schiff, Darryl Maher	2006	9
17	Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia European Journal Of Haematology ·Frank Firkin, Darryl Maher	1988	8
18	T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells Cancer Immunology Immunotherapy ·Qiyuan Chen, Melanie Smith, Tam Nguyen, Darryl Maher, Peter Hersey	1994	7
19	Efficacy, Safety and Pharmacokinetics of a Novel Subcutaneous Immunoglobulin, Evogam®, in Primary Immunodeficiency Journal of Clinical Immunology ·Marianne Empson, Mimi L.K. Tang, Lisa K. C. Pearce, Leon Rozen, Michael S. Gold, Constance H. Katelaris, David Langton, Joanne Smart, William Smith, Richard Steele, John B. Ziegler, Darryl Maher	2012	6
20	Rubella antibodies in Australian immunoglobulin products Human Vaccines & Immunotherapeutics ·Megan K Young, Joseph Bertolini, Pushpa Kotharu, Darryl Maher, Allan W. Cripps	2017	4

About Darryl Maher

Darryl Maher is a scholar working on Immunology, Epidemiology, Oncology, Hematology and Genetics, having authored 23 papers that have together received 1.3k indexed citations. Recurring topics across this work include Neutropenia and Cancer Infections (5 papers), T-cell and B-cell Immunology (3 papers), Immune Cell Function and Interaction (3 papers), Blood groups and transfusion (3 papers), Blood disorders and treatments (3 papers), Platelet Disorders and Treatments (3 papers), Immunotherapy and Immune Responses (3 papers) and Immune Response and Inflammation (3 papers). The work is most often cited by research in Immunology (720 citations), Hematology (186 citations), Oncology (324 citations), Pulmonary and Respiratory Medicine (276 citations) and Immunology and Allergy (43 citations). Darryl Maher has collaborated with scholars based in Australia, Belgium and United Kingdom. Frequent co-authors include Jonathan Cebon, Ashley R. Dunn, Edouard G. Stanley, John A.M. Gall, Vincent Sinickas, D Metcalf, Graham J. Lieschke, D Grail, G. S. Hodgson and Peter Hersey. Their work appears in journals such as Human Vaccines & Immunotherapeutics, Cancer Chemotherapy and Pharmacology, Journal of Clinical Oncology, Critical Care Medicine and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact